Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
The progress in synthetic organic chemistry keeps turning up compounds with better precision. 2-((2,6-Difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid did not pop up overnight. It owes its design to decades of research in heterocyclic chemistry, driven by the search for molecules that blend specificity with functional potential. Thiophenes first captured attention as early as the 19th century because of their stability and ready modification. Once medicinal chemists started looking at tailor-making them for drug discovery, structures like this one started appearing in research papers and pharma filings. Fluorinated benzyl groups made their mark for their role in modulating potency. The backbone borrows from both surgical fine-tuning and necessity—coming together around the turn of the century as analytical tools improved. Behind every mouthful of a chemical name, there’s a crawl of published reaction routes, patent races, and academic footnotes.
This compound stands out for its complexity, joining together a thiophene ring with substituted benzyl, amino, nitro, and carboxylic acid groups. The structure signals versatility—ready to anchor a pharmacophore or serve as a structural intermediate. BP, EP, and USP grades underline the demand for consistency and purity, a nod to its arrival on the pharma scene as more than a chemical curiosity. Its combination of electron-withdrawing fluorine atoms and a bulky nitrophenyl group creates options for targeting biological receptors. Many modern APIs, especially those working in inflammation, oncology, and antimicrobial research, call out for scaffolds with similar complexity because these patterns interact well with key enzyme sites.
This compound appears as a pale yellow crystalline powder under room conditions. The molecular weight lands just over 470 g/mol, making it light enough for quick cell permeability assays, but substantial enough to force thoughtful formulation work. Melting point usually hovers in the range of 145-150°C, influenced by the strength of intramolecular hydrogen bonding and the presence of both lipophilic and hydrophilic zones. Solubility patterns tell much of the story: sparing in plain water, but much improved in DMSO or DMF, echoing a balance between polar and nonpolar sections. The thiophene core gives UV activity, often used in quick checks for purity. Stability under ordinary lighting sits at acceptable levels, though extended exposure to high temperatures or strong acids triggers decomposition and loss of functional groups.
Packages come with stringent batch information, analytic certification, and traceability tags reflecting pharmacopeial standards. Typical stated purity exceeds 99% by HPLC, with identified residual solvents below 0.1%. Moisture content stays under 0.5%, and specific rotation remains within a tight window defined by the certified reference standard. Heavy metal screenings are a mandatory footnote—lead under 10 ppm, arsenic faded to below 2 ppm. Instinct pushes handling with gloves and goggles, but the labeling reminds even the best-trained teams: store at 2-8°C, in the dark, and keep it dry. Full traceability comes on every container, linking to batch production records, QC sheets, and MSDS on file. Each batch gets a color-coded hazardous material identifier to make storage and transport more reliable across labs.
Manufacturing calls for layered synthesis. The starting material often includes commercially available thiophene-3-carboxylic acid, which gets activated for nucleophilic substitution. The dimethylamino group is introduced by formaldehyde and dimethylamine condensation under controlled pH. The benzylation step uses 2,6-difluorobenzyl bromide, tied up with strict temperature management to keep side products low. The coupling with the ethoxycarbonyl group needs classic Schotten–Baumann conditions, linking up the amino group through carbamate formation. Final introduction of the nitrophenyl moiety uses a Suzuki-type cross-coupling, leveraging palladium catalysis and tailored boronic acids. The endgame: slow crystallization in anhydrous ethyl acetate, with repeated washing and vacuum drying. Each phase receives TLC checks and HPLC profiling to pin down purity ahead of scale-up.
Further functional tweaks remain possible at each of the core positions. The carboxylic acid can be converted into esters or amides for prodrug experiments or for tuning bioavailability. Nitrophenyl position stands open for reduction to an amino derivative, opening doors to peptide coupling or further diazotization. The dimethylamino group supports quaternization, which can swing the balance between cell uptake and hydrolytic stability. The difluorobenzyl moiety, thanks to its electronegativity, resists most mild nucleophiles, but targeted reactions using strong bases prise loose the substitution at select positions. The molecule’s skeleton works as a modular hub for medicinal chemists searching for tight SAR (structure activity relationship) insights. Many academic labs have already published tweaks using either metal-catalyzed cross-coupling or selective reductions to tailor-make analogues that show altered biological profiles.
Across catalogs, this molecule often appears under several aliases, such as the “difluorobenzyl carbamate thiophene acid”, but also under coded research numbers specific to each commercial supplier. Internal documents within pharma R&D teams tag it by lot and batch code, cross-referencing global chemical registries like PubChem or ChemSpider. Patent filings use both full IUPAC names and shorthand descriptors, which can tie to research programs in anti-inflammatory, anti-infective, or cytostatic spaces. The synonyms in daily use typically boil down to its major substituents, for ease of reference across experimental logs and order sheets.
If you have spent time in a process chemistry lab, you know the real risk sits with exposure—not so much from acute toxicity, but long-term irritation. These heterocyclic compounds, especially with nitro and fluorine atoms in the mix, demand a watchful handling style. Safety data points to skin and mucous membrane irritation, and inhalation of dust raises concerns. Good lab practice dictates the use of fume hoods, nitrile gloves, and splash goggles for even basic transfers. Disposal routes matter—those nitro groups cannot just go down the drain due to regulated waste streams, so containment and dedicated solvent neutralization should follow up every session. Each process batch needs secondary containment, dated logs, and signed-off waste manifests for every run. Pharmacopeial grade here means not just the right chemistry on paper, but total traceability—where, who, how, and what next for every gram produced.
In the last decade, this compound’s type has found a home in high-throughput screening cycles, sitting at the center of new lead identification efforts. Oncology programs value the electron-rich thiophene ring for kinase and receptor binding studies. Anti-infective research looks to the fluorinated motifs for membrane permeability and metabolic resistance. Formulation scientists tap these compounds for new salt forms, testing how structural modifications affect oral bioavailability, solubility, and metabolic stability. The USP-grade usability amplifies acceptance: no one wants to run a trial with a compound that falls short of international standards, especially as regulatory pressures bite harder. Many proprietary drug conjugate designs now tie in backbone structures like this one for targeted delivery and controlled-release murals—a far cry from the single-action molecules of a generation ago.
R&D teams aren’t shy about using every functional group this molecule offers. The electron-donating dimethylamino group, for example, opens up routes for tuning selectivity in in vitro screens. Bioconjugate chemistry borrows the carboxylic acid for pegylation or protein tagging, expanding the pharmacokinetics in animal models. Some preclinical groups focus on labeling this scaffold with isotopes using the easily modifiable positions to enable PET or SPECT imaging—useful for tracing drug pathways. The nitrophenyl ring couples smoothly to extend the molecule in a range of combinatorial libraries, and medicinal chemists keep probing the impact of the difluorobenzyl group by swapping in new substituents. These efforts feed a pipeline of papers, patents, and clinical protocols. The presence of BP, EP, and USP documentation accelerates transfer to industry because paperwork must match physical properties exactly before batch transfer.
Toxicological studies tend to start with in vitro cytotoxicity evaluations, looking for red flags such as DNA cross-linking potential or mitochondrial disruption. Early data from animal models with similar compounds show that chronic dosing raises liver enzyme levels, suggesting metabolic breakdown products may put strain on detoxification pathways. Testing has not yielded strong evidence for acute systemic toxicity in mammals at the low-dose range typical for exploratory dosing, but irritation and mild inflammation at administration sites have appeared consistently. Regulatory filings require repeat-dose and genotoxicity studies, with emphasis on breakdown product identification, especially where nitro groups reduce to potentially reactive amines in vivo. The fluorinated sections add a wrinkle—compounds with similar motifs last longer in the environment, putting pressure on downstream waste management. Full MSDS coverage flags eye and respiratory risk, so no shortcut exists for working safely over the course of a project.
The push for new chemical entities with targeted activity keeps the attention on multitasking molecules like this one. Advances in combinatorial synthesis and machine learning powered drug design reward frameworks that can take a beating from modification without losing shape or activity. As personalized medicine protocols firm up, templates with multiple attachment points and predictable pharmacology, like this thiophene acid, ride the next wave of bioconjugation and targeted therapy projects. Green chemistry trends are also pushing for new, cleaner synthetic routes for complex heterocycles, spurred by regulators and big pharma sustainability pledges. The future has this molecule not only powering development pipelines but reshaping safe, scalable preparation for clinical and commercial manufacturing, with every part of its structure put to the test in real therapeutic contexts.
Every so often in the pharmaceutical industry, a molecule carries more weight than its name suggests. 2-((2,6-Difluorobenzyl)(Ethoxycarbonyl)Amino)-4-((Dimethylamino)Methyl)-5-(4-Nitrophenyl)Thiophene-3-Carboxylic Acid, despite the mouthful, falls in this category. This compound stands at the frontier of new possibilities for drug synthesis. Its structure offers several reactive sites, making it an essential building block in the synthesis of advanced pharmaceutical compounds.
Chemists rely on compounds like this to set the stage for next-generation treatments. In a crowded market where precision and safety take priority, the unique backbone of this molecule supports the creation of anti-infective medicines, targeted therapies, and drugs for complex diseases. The difluorobenzyl and nitrophenyl groups enhance its value, as these groups often tailor molecules for better biological activity, improved stability, and increased selectivity.
Early-stage research programs have benefited. Medicinal chemistry teams deploy it to build analogues with modified activity or bioavailability, pushing for better patient outcomes. Documented use in some patented synthetic routes reveals its critical role, especially in studies aiming for more effective enzyme inhibitors or receptor agonists.
In my experience, regulatory grade matters as much as innovation. BP, EP, and USP grades exist not for the sake of bureaucracy, but to guarantee safety in every vial or tablet. Labs and manufacturers that hold to these standards, guided by years of closely monitored quality control, protect end users from harmful impurities or batch-to-batch inconsistencies. This isn’t just paperwork—one missed detail in quality testing can mean hospitals receive substandard therapy, and lives hang in the balance.
Real pharma jobs require visible paper trails and clean, documented workflows. So, seeing this molecule available at BP, EP, and USP pharma grade becomes a signal for professionals that the product stands up to scrutiny. This assurance feeds downstream decisions, from scale-up to storage, packaging, and finally, patient use.
Access remains a challenge for smaller biotech teams and academic labs. Large suppliers focus on commercial volumes, which puts smaller players at a disadvantage. Affordable small-batch supply of this molecule, at consistent pharma grade, unlocks fresh chances for early-stage innovators to get their ideas tested. Support structures like public-private partnerships or consortia can ease this path, connecting producers with research groups focused on rare diseases or antimicrobial breakthroughs.
Demand for well-characterized building blocks like this grows as personalized and precision medicine continues its rise. From anti-inflammatory agents to new antibiotics, the flexibility woven into this compound’s structure helps drive the search for smarter therapies. A focus on sustainability in its manufacturing process will help reduce environmental impact, further aligning the industry with public health and safety.
Keeping this compound accessible—at strict quality, fair price, and low environmental cost—challenges both industry leaders and regulators. Investment in transparent supply chains, robust analytical tools, and responsive support forces long-term change for the better.
Lab work can get messy fast without real guardrails for quality. Over the years, I’ve stood in plenty of pharmacies and research hubs, flipping through pages of thick pharmacopoeias. Each country swears by its own, yet global science leans hard on three: the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). These aren’t just dusty reference books—they’re the law for anyone who handles pharmaceuticals.
Purity wraps around more than just an absence of dirt. It dives into unseen threats: chemical cousins that snuck through synthesis, trace metals from pipes, organic leftovers, and even the water in a tablet. BP, EP, and USP set numbers so that each batch runs clean, keeps patients safe, and reaches shelves everywhere from Cairo to Kansas. It’s pretty common to see the standard for a pure compound clock in at no less than 99.0%—sometimes higher for injectable or highly sensitive products. Anything outside this window is a red flag. Tiny amounts of related substances or heavy metals may slip in, but only up to strict cut-offs.
I remember sorting through assay results, seeing how each pharmacopoeia might look for the same flaws, but use its own recipe. BP loves specific chemical spot tests, laying out upper limits for any single impurity, plus a cap for the sum of all possible troublemakers. The EP leans into the same approach, but it might toss in extra checks for substances people only started worrying about last year. The USP always brings out the heavy artillery for identity checks, ruling out mistakes with more modern techniques. Chromatography, titration, sometimes atomic absorption—these show up over and over for good reason. Anyone working in QC will tell you, it’s nearly impossible to fudge these tests.
Global trade drives this juggling act. One pharma company might fill contracts across the UK, Europe, and the US in a single day. You miss a standard, you lose a market. Patients pay the true cost. Even a tenth of a percent off spec can hike up toxicity risks, or wipe out a drug’s helpful punch. Regulators and customs officials pore over certificates, cross-referencing every line with BP, EP, and USP numbers to catch anything that could cause harm. It’s not about fussy paperwork—it’s about trust.
Labs and factories can run into trouble matching standards from three books at once. Some resort to setting their own house standard—the tightest number from all three—instead of trying to keep a roster of “BP grade” or “USP grade” lots sitting in stock. Automation and stronger data tracking help pull in results from every batch, scan for outliers, and raise a flag before anything ships. The real issue? Training the next round of chemists to see these numbers as life-and-death instead of just regulatory hoops to jump through. Boots-on-the-ground teaching and sharper guidelines mean fewer accidents, less waste, and less risk down the supply chain.
The numbers lining BP, EP, and USP aren’t set in stone, but they form the backbone of medicine safety across continents. For anyone involved in compounding, wholesale, or direct care, these standards mark a bright line: stick to them, and you’re doing your part to protect people. Ignore them, and you’re gambling with someone else’s health. The more we talk about what these numbers mean, the better we get at keeping medicine clean and reliable for everyone who needs it.
Trying to keep products stable over time isn’t just about sealing a container and hoping for the best. I learned that lesson the hard way, watching medications lose their punch and food spoil before the date on the label, all because of poor storage. Stability is about preserving chemical and physical properties, not just stretching out the use-by date. Skipping proper storage leads to wasted money, lost trust, and sometimes even safety hazards.
Temperature ranks as the big player in the stability game. Most products don’t thrive in extremes. Leave chocolate in the sun, and you’re scraping it off the wrapper. High temperatures speed up chemical breakdown and feed bacteria and mold. Dressings, creams, supplements, and even electronics keep their quality longer at room temperature—somewhere between 15°C and 25°C. Step above 30°C and you’re aging a product five times faster than expected, according to studies on chemical decay rates. Cold isn’t always better. A medicine meant for room temp turns unstable once frozen, then thawed.
Moisture sneaks into packages and quietly ruins what’s inside. I’ve seen powders clump and lose their blend. Dried foods get soggy and stale in humid air, even if you don’t notice at first. Silica packets or desiccant sachets can pull moisture away, but packaging must be tight. For best results, the storage area should stick below 60% relative humidity, with some products calling for even less. The U.S. Pharmacopeia sets similar standards for drug storage, and countless recalls follow when someone skips these guidelines.
Sunlight might seem harmless on a shelf, but its UV rays can shatter delicate vitamins, fade dyes, and even set off harmful reactions. Protecting goods in tinted or opaque packaging helps. Pharmacy shelves look dimly lit for a reason. Vials, creams, and oils last longer in the dark. If the label warns against light, there’s science behind it.
Oxygen does more than make metals rust. For many products—especially oils, supplements, and processed foods—it kicks off unwanted reactions. I once tossed out a whole batch of fish oil capsules that smelled like rotten eggs from oxidation. Sealing containers tightly, flushing packaging with nitrogen, or using oxygen absorbers can hold off chemical changes. This approach stretches shelf life, keeps nutrients stable, and blocks spoilage.
Every warehouse or home pantry benefits from the same basic rules: keep packaging tightly closed, shelter products from sunlight, aim for a cool, dry spot, and keep oxygen away when possible. Strong, layered packaging, along with smart placement away from hot equipment, goes a long way. Sticking to manufacturer storage instructions gives the best shot at lasting stability. While technology may offer smart fridges or humidity monitors, simple routines like regular resets and lost-batch culls also protect every dollar spent. Keeping conditions steady brings the peace of mind that what goes in the box comes out just as intended.
Anyone who works in a lab or a manufacturing site knows the drill. A compound seems perfect for a new project, so a quick search brings up a supplier with the right grade and price. Right here, one question matters more than any discount or fast shipping: Can you get a Certificate of Analysis and a Material Safety Data Sheet?
I've lost count of the times a new reagent showed up, only for colleagues to realize nobody checked the CoA or the MSDS. Without those two documents, it’s like cooking blindfolded and hoping nothing’s poisonous. The Certificate of Analysis comes straight from the batch lab. It lays out what’s inside, with a clear breakdown of purity, any tested contaminants, and actual batch test data. Many suppliers post glossy product photos, but the CoA tells what really landed in your bottle.
The MSDS, now more often called the SDS, tells you—up front—about the risks. Not just the kind about inhaling dust or spilling on your skin. It maps out what happens if it catches fire, reacts with something nearby, or goes down the drain. I've seen reactions turn sideways because someone “just assumed” the material handled like all the others. It didn’t, and that day taught a lesson nobody wanted to repeat.
Rules across the world—from REACH in Europe to OSHA’s HazCom—don’t ask if you feel like organizing your safety paperwork. They demand it. Labs that cut corners find the truth soon enough. Auditors and inspectors don’t joke around about tracking chemical origins. Fines stack up quickly, but the worst cost hits the team. A hospital visit for a burned arm or a lungful of fumes changes how people look at safety for good.
That’s why the serious suppliers show their cards. They offer downloadable CoAs and SDS for every batch, sometimes even before payment clears. If a supplier hesitates, can’t produce documents in a language you understand, or claims “it’s not available,” it’s time to walk away. There are enough sellers—nobody has to gamble with what lands in the fume hood.
Some companies only offer generic documents, not tied to a lot number or batch. That’s a red flag. The best suppliers add batch-specific CoAs and a current, complete SDS. Those who care about long-term business respond fast to requests and help explain any odd test results or data you spot on the documents.
It pays to read the details, too. A high purity isn’t helpful if a hidden contaminant matters for your application. I once chased down trace metals with a supplier after spotty experiment results. Digging into their CoA, we found something everyone missed—a metal ion that changed the outcome. Fixing it cost time, but at least the paperwork caught the issue before product shipped to a customer.
Ordering chemicals can move fast, but skipping the basics is a shortcut to trouble. Always ask for the Certificate of Analysis and the SDS before you order or open anything. Check the batch numbers, match the lot to your shipment, and make sure the SDS covers all the hazards for your workspace. If you’re not sure, a short call or email to the supplier solves problems before they start. Good science (and safe work) relies on more than luck—it relies on facts, and those should always come with the box.
Working with pharmaceutical-grade chemicals demands a steady focus on safety. Every time I’ve handled these materials, there’s never been room for shortcuts. Gloves and lab coats aren’t just a good habit—they’re a daily necessity, shielding your skin from toxic powders or corrosive spills. Chemical labels and Safety Data Sheets aren’t paper clutter; they spell out in plain terms what to expect if something goes wrong. I’ve seen too many near misses in the lab from ignoring a warning, so reading up before opening a new container has saved more than just time.
Some people believe cracking a window is enough to handle volatile or dusty chemicals. They learn the hard way—chemical fumes don’t just irritate the eyes and nose. In my experience, working inside a certified fume hood is a non-negotiable step any time airborne exposure is a possibility. Proper ventilation does more than dilute problems, it keeps toxic vapors out of the lungs. OSHA and CDC point to hundreds of incidents each year tied to neglecting this basic rule.
There’s a right place for every chemical, and the wrong spot can lead to fires or toxic reactions. I always check if a compound demands flammable-proof storage or protection from sunlight. Segregating acids from bases, or oxidizers from organics, might feel like overkill until a splash or unexpected reaction happens. Labels on storage cabinets and thorough records make tracking stock easier, but more importantly, accidental mix-ups go down to zero when everything has a clear home.
Goggles may fog up, gloves might seem bulky, but skipping out is a rookie mistake. The CDC and NIH both emphasize that eye protection stands between you and blindness if a splash occurs. I pick gloves based on chemical compatibility, as some solvents burn straight through latex. Respirators aren’t for show; powder inhalation or vapor exposure can send someone to the ER. Safety showers and eyewash stations stand ready for emergencies, but it’s better not to need them at all.
Minor spills look easy to wipe up. They’re also where hazards hide. I’ve cleaned up enough chemical dust and liquid to know that trying to improvise with paper towels only spreads the problem. Labs need spill kits tailored to the compounds in use, including absorbent materials and neutralizing agents. Training drills might feel repetitive, but muscle memory can be the difference between containment and chaos.
I’ve watched both newcomers and seasoned chemists catch mistakes before they escalate—all because everyone followed procedures. No one memorizes emergency protocols in a day. Regular training, reinforced by checklists and real-life walkthroughs, embeds caution into the daily routine. Every incident, near-miss, or break in routine should be logged so the same error never happens twice.
Over time, a lab or pharmacy grows safer not because of written rules but because every person feels real responsibility. Leaders set the tone by practicing what they preach and encouraging questions. No one gets brushed off for reporting a near miss. That openness drives improvements, making safe chemical handling not just a regulation, but a standard everyone demands—from top to bottom.
Chengguan District, Lanzhou, Gansu, China
